STRATEGIC ALLIANCE OF NOVARTIS

NOVARTIS
Alliance between Novartis and Microsoft (Sept 1, 2019)

● Novartis and Microsoft announced a multiyear alliance which will leverage data &
Artificial Intelligence (AI) to transform how medicines are discovered, developed and
commercialized.
● This alliance will create more-personalized customer experiences with the aim of
reaching twice as many patients twice as fast
● The alliance will also increase R&D investments by cutting operational costs by at least
$1 billion and perhaps as much as $2 billion.
● For Microsoft, partnering with Novartis gives it opportunities to test its AI technology for
precise uses like in CAR-T therapy manufacturing, as well as at scale across a global
company
● Driving force: Race for the world through co-specialization & learnings generated

Alliance between Novartis and Intercell alliance (July 2, 2007)

● Novartis has increased its stake in Austrian biotechnology firm Intercell and signed a
deal worth at least 270 million euros to get access to a number of promising vaccines.
● Novartis obtains opt‐in rights for the development, manufacturing and commercialization
of Intercell’s non‐partnered novel vaccine targets after the completion of Phase II clinical
trials (or earlier at Novartis’s election).
● It will focus on the development of bacterial vaccine products derived from Intercell’s
Antigen Identification Program (AIP®) as well as the use of Intercell’s adjuvant
technology (IC31®) in selected new vaccines.
● Intercell retains the right to choose between a co‐development/profit sharing or a
licensing arrangement on predefined milestones and royalty payments for products that
Novartis takes forward.
● Driving force: Race for the world through co-specialization & learnings generated

Alliance between Novartis and Infinity (Jan 2005)

● Novartis entered into an R&D collaboration with Infinity Pharmaceuticals Inc. to jointly
design a collection of novel small molecules, which would be synthesized by Infinity.
● This collaboration provides expertise in developing smart chemical libraries with Novartis
in drug discovery and development in order to bring innovative therapies to patients.
● Driving force: Race for the world through co-specialization & learnings generated

Alliance between University of California Berkeley and Novartis (Sep 2017)

● Goal of unlocking challenging drug targets in order to speed up the discovery of new
medications in areas like infectious diseases and cancer.
● Next-generation therapeutic methods will be developed to target the enormous number of
disease targets in cancer and other illnesses that have escaped standard small-molecule
drugs and are currently considered "undruggable."
● This collaboration provides potential to promote essential chemoproteomics research
● Look into the potential of degraders, which are bifunctional molecules that bind to disease
targets on one end and component in a cell's natural protein on the other.
● Driving force: Race for the future through co-specialization & learnings generated

Alliance between Alnylam and The Novartis Institutes for BioMedical Research
(Sep 2005 & Jan 2022)

● It used Alnylam's proprietary siRNA technology to inhibit a target discovered at the Novartis
Institutes for BioMedical Research, leading to the development of a treatment to promote
the regrowth of functional liver cells as an alternative to liver transplantation.
● During the three-year exclusive research agreement, Alnylam designed and tested possible
siRNAs utilising Novartis' target-specific assays. Novartis performed further development
and clinical testing once a lead candidate has been selected.
● Driving force: Race for the future through co-specialization & learnings generated

Alliance between Swiss Tropical and MMV & Novartis Institute for Tropical
Diseases (Jun-2016)
KAF156 is the result of a alliance between the Novartis Institute for Tropical Diseases, the
Novartis Research Foundation's Genomics Institute, and the Swiss Tropical and Public Health
Institute funded by the Wellcome Trust, Medicines for Malaria Venture (MMV), and the
Singapore Economic Development Board.

● First high-quality artemisinin combination medicine developed exclusively for children being
launched in 2009.
● Novartis has provided malaria-endemic countries with more than 300 million dispersible
paediatric medicines at no cost.
● Driving force: Race for the future through co-specialization & learnings generated

Alliance between Endocyte and Novartis (2018)

Endocyte had acquired exclusive worldwide rights to develop and commercialize PSMA-617
agents in 2017, to build a leading radioligand (RLT) portfolio and create value for patients and
shareholders alike. Novartis recognized the potential for 177Lu-PSMA-617 to change the
treatment landscape for men with metastatic castration-resistant prostate cancer (mCRPC), as
well as the broader role that RLTs may potentially play in the treatment of cancer. The global
reach and expertise of Novartis in developing and commercializing RLT therapies would allow
patients to benefit from these therapies as quickly as possible.

● Novartis added 177Lu-PSMA-617, a potential first-in-class radioligand therapy to bolster

its offering in its radiopharmaceuticals business.
● Novartis strengthened leadership in nuclear medicine and radioligand therapy for cancer
 ● Complements the robust Advanced Accelerator Applications radioligand therapy pipeline
of Novartis
● Endocyte offers radiopharmaceutical programs with significant sales potential
● Driving force for Alliance: Race for the future through co-specialization

Alliance between Quaker and Novartis (2000)

The Quaker Oats Co. (Chicago, IL) formed a joint venture with Novartis Consumer Health, Inc.
(Summit, NJ) to form Altus Food Co., a new functional foods company. Partnering with Novartis
Consumer Health moved both companies' exploration into functional foods ahead much faster
and more efficiently than either company could accomplish alone.

● Jointly pursued the growth of the functional foods market

● Novartis' product development skills and consumer health care business complement
Quaker's consumer food marketing expertise and brand leadership. Quaker is credited
with dramatically growing one of North America's most successful brand-name functional
foods, Gatorade.
● Novartis Consumer Health has the nutrition knowledge and clinical research skills
necessary to create superior products, but it also is a leader in functional foods. Its
launch of the Aviva brand in Europe is one example
● Altus would have access to Quaker's brand marketing and selling, nutrition science,
taste technology and manufacturing to pursue leadership in functional foods
● "Quaker Oats' expertise in consumer marketing would benefit the products that the new
company, Altus will be distributing
● Driving force for Alliance: Race for the world through co-specialization

Alliance between Dunad and Novartis (2021)

● Novartis would fully fund the partnership and hold an option to develop and market
therapies resulting from the alliance. On exercising the option, Novartis will handle future
development, production and international marketing of the treatments generated
against the four targets.
● Novartis would pay $24m upfront in cash and equity to Dunad apart from substantial
funds to support research. Furthermore, Dunad would be eligible to receive discovery,
development, regulatory and milestone payments based on sales, which were expected
to aggregate to up to $1.3bn and royalty payments.
● The alliance would leverage the customisable and selective platform of Dunad to
develop the new orally bioavailable covalent drugs for up to four targets. Utilising mono-
valent small molecules, the platform stimulates the selective breakdown of disease-
causing and frequently undruggable proteins by altering the target directly.
● Dunad would advance the programmes to the lead optimisation stage while Novartis
would offer expertise on target and ligand, as well as extend access to distinctive tests
and models.
 ● This collaboration was an important milestone for Dunad. It allowed rapid expansion of
the impact of its platform technology to additional target classes and therapeutic areas,
beyond Dunad’s own internal target pipeline.
● Driving force for Alliance: Race for the world through co-specialization & learnings
generated

Alliance between BASF, Deutsche Bank, LafargeHolcim, Philip Morris

International, Bosch, SAP and SK(20-Aug-2019)

● The Novartis financial, environmental and social (FES) impact valuation is an approach
to measuring the social and environmental impact of business activities on society, in
addition to economic value. In 2017, this approach showed that their activities
contributed USD 84 billion to the global gross domestic product (GDP), as well as an
estimated 830 000 jobs beyond those held by the company's own employees.
● Driving force for Alliance:
● A non-profit alliance addressing the need to rethink the value contribution of
business as it pertains to capital.
● The alliance aims to create a standard for measuring and disclosing the
environmental, human, social and financial value companies provide to society.

Alliance between Quebec and Novartis(November 20, 2019)

● Alliance reinforces need for innovation in healthcare through new digital technologies
and data science. Novartis' announcement is an important step in reimagining medicine
beyond the traditional pharmaceutical operating model to find creative solutions to
healthcare problems.
● Driving force for Alliance: Novartis Pharmaceuticals Canada Inc. announced a
strategic alliance with Mila as the company embraces the next chapter of healthcare
innovation with new digital technologies and data science. This alliance with Mila
underpins the Novartis commitment to leverage data and artificial intelligence (AI) to
transform how medicines are discovered, developed and commercialized. Alliances like
this will help them go beyond the traditional pharmaceutical industry operating model to
embrace the future of healthcare innovation to deliver on their purpose to reimagine
medicine to improve and extend lives.

Alliance between Verily and Novartis(May 21, 2019)

● Less than 10% of the population across the US participates in the clinical trials process.
Furthermore, there are challenges in research, which include data fragmentation,
inefficient operations and limited value for patients.
● Verily, along its industry partners, aims to implement a technology-enabled approach in
conducting research, and increase the number and diversity of clinical research
participants.
 ● The firms will also explore new methods to generate real-world evidence using the
Baseline Platform to gather, organise and activate health information from electronic
health records, sensors and other digital sources.
● Driving force for Alliance: Verily, an Alphabet company, announced a strategic
alliance with Otsuka and other pharmaceutical companies to develop digitally innovative,
patient-centered clinical research programs using Project Baseline's evidence
generation platform and tools.

Alliance between Novartis and Beigene(Dec 20, 2021)

Novartis signed a deal with Beijing-based biotech BeiGene that will strengthen its
immunotherapy pipeline with the addition of late-stage TIGIT inhibitor, ociperlimab. Also, these
two companies identified multiple combination therapy clinical trial opportunities related to solid
tumors.
● Novartis gains access to antibody Ocipermilab developed by BeiGene, expanding the
company’s research and development activities in immuno-oncology
● BeiGene grants Novartis rights to develop, manufacture, and commercialize tislelizumab
in North America, Europe, and Japan through a collaboration and license agreement
● Market development partnership is expected to grow Novartis Oncology’s presence in
China by leveraging BeiGenes existing presence there. The company is committed to
bringing novel treatments to patients
● Driving force: Racing for the future with Co Specialization

Alliance between Novartis and Amgen(Sep 1, 2015)

The collaboration propelled Amgen's potential entry into Alzheimer's disease by teaming up with
Novartis to aid genetically predisposed individuals at risk of developing Alzheimer's disease. It
also enabled Amgen to focus on the commercialization of its migraine programs in the U.S.,
Canada and Japan, while leveraging Novartis' strong commercial capabilities in neuroscience
throughout Europe and other markets worldwide.
● Novartis will receive global co-development rights and commercial rights outside of the
U.S., Canada and Japan to the investigative molecules in Amgen's migraine portfolio
program.
● The agreement combines each company's BACE (beta-site APP-cleaving enzyme-1)
programs targeting Alzheimer's disease into a global co-commercialization and co-
development arrangement.
● In exchange for territory rights, Novartis will fund disproportionate amounts of global
R&D expenses for an agreed-upon period on the migraine programs and pay Amgen
double-digit royalties on sales.
● Driving force: Racing for the world & future through Co Specialization

Alliance between Novartis and Penn (2012)

 ● Penn and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for
Cancer Patients, to further study and commercialize novel cellular immunotherapies
using chimeric antigen receptor (CAR) technologies.
● Penn grants Novartis an exclusive worldwide license to the technologies used in an
ongoing trial of patients with chronic lymphocytic leukemia (CLL) as well as future CAR-
based therapies developed through the collaboration.
● Novartis will invest in the establishment of the Center for Advanced Cellular Therapies
and future research of the technology. The center will be devoted to the discovery,
development and manufacturing of adoptive T cell immunotherapies through a joint
research and development program led by scientists and clinicians from Penn, Novartis,
and the Novartis Institutes for Biomedical Research.
● Driving force: Racing for the future though Co Specialization

Alliance between Novartis and Bayer Schering AG (Jan 2005)

● Novartis and Bayer Schering AG collaborated in the development of PTK/ZK, an oral

angiogenesis inhibitor used to slow the spread and growth of tumors.
● Under a January 2005 agreement, Novartis and Schering will co-promote the drug.
● Schering will become the lead partner in Europe while Novartis will be the lead partner in
North America.
● The lead partner will bear the larger part of costs and resources, and will thus retain a
correspondingly larger percentage of the profits.
● Driving force for Alliance: Race for the world through co-specialization & learnings
generated.

Alliance between Novartis and P&G (2003)

● Novartis acquired Enablex, known as Emselex in Europe, from Pfizer.

● Prior to the Novartis-P&G arrangement, Novartis was marketing the drug, used to treat
incontinence, exclusively in the U.S.
● Their marketing collaboration with P&G was intended to increase their force in the
worldwide market, estimated by the Pharmaceutical Business Review at $1.5 billion.
● Driving force for Alliance: Race for the world through co-specialization & learnings
generated.

Alliance between Novartis and Idenix (2003)

● Novartis and Idenix Pharmaceuticals entered into an $862 million strategic alliance to
developing and co-promote its hepatitis B and hepatitis C product candidates.
● The agreement provides that Novartis and Idenix will co-promote in the United States,
France, Germany, Italy, Spain and the United Kingdom.
● Novartis holds the exclusive license to these product candidates in the rest of the world.
● In 2003, Novartis purchased a majority share of Idenix.
● Driving force for Alliance: Race for the world through co-specialization & learnings
generated.